Target enrichment improves culture-independent 1

detection of Neisseria gonorrhoeae direct from sample 2

- with Nanopore sequencing. 3
- 4

1. Author names 5

Teresa L. Street^{1,2*}(ORCID: 0000-0001-8491-240X), Nicholas D. Sanderson^{1,2*}(ORCID: 0000-6 0001-6370-1961), Leanne Barker¹, James Kavanagh¹, Kevin Cole,³ The GonFast Investigators 7

- Group, Martin Llewelyn³, David W. Eyre^{2,4} (ORCID: 0000-0001-5095-6367) 8
- 9

2. Affiliation(s) 10

- 11 ¹Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK;
- 12 ²National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe
- 13 Hospital, Oxford, UK;
- ³Department of Microbiology and Infection, University Hospitals Sussex NHS Trust, Brighton, 14 15 UK:
- 16 ⁴Big Data Institute, Nuffield Department of Population Health, University of Oxford, UK.
- 17 ^{*}These authors contributed equally to this manuscript. Author order was determined by
- 18 mutual agreement.
- 19

20 Corresponding author and email address 2.1

- 21 Teresa L. Street
- 22 teresa.street@ndm.ox.ac.uk
- 23

24 2.2 **Keywords**

25 Neisseria gonorrhoeae, target enrichment, culture-independent, Nanopore sequencing,

- 26 SureSelect, AMR.
- 27

28 2.3 **Repositories**

29 European Nucleotide Archive study code PRJEB64347.

3. Abstract 30

- 31 Multi-drug resistant *Neisseria gonorrhoeae* infection is a significant public health risk.
- Rapidly detecting N. gonorrhoeae and antimicrobial resistant (AMR) determinants by 32
- metagenomic sequencing of urine is possible, although high levels of host DNA and 33
- 34 overgrowth of contaminating species hamper sequencing and limit N. gonorrhoeae genome
- 35 coverage. We performed Nanopore sequencing of nucleic acid amplification test-positive
- 36 unite varageles and to uture and statives uper tenates walks with a varie to any the utoprobed based danger actice.

enrichment, using a custom SureSelect panel to investigate selectively enriching for N. 37 38 gonorrhoeae DNA. Probes were designed to cover the entire N. gonorrhoeae genome, with 39 10-fold enrichment of probes covering selected AMR determinants. Multiplexing was tested 40 in subset of samples. The proportion of sequence bases classified as N. gonorrhoeae 41 increased in all samples after enrichment, from a median (IQR) of 0.05% (0.01-0.1%) to 76% 42 (42-82%), giving a corresponding median improvement in fold genome coverage of 365-43 times (112-720). Over 20-fold coverage, required for robust AMR determinant detection, 44 was achieved in 13/15 (87%) samples, compared to 2/15 (13%) without enrichment. The 45 four samples multiplexed together also achieved >20x genome coverage. Coverage of AMR 46 determinants was sufficient to predict resistance where present, and genome coverage also 47 enabled phylogenetic relationships to be reconstructed. Probe-based target enrichment can 48 improve N. gonorrhoeae genome coverage when sequencing DNA extracts directly from 49 urine or urethral swabs, allowing for robust detection of AMR determinants. Additionally, 50 multiplexing prior to enrichment provided enough genome coverage for AMR detection and 51 reduces the costs associated with this method.

52

4. Impact statement 53

54 *Neisseria gonorrhoeae* infection presents a significant public health risk, with multi-drug 55 resistance present globally. Early detection helps control the spread of antimicrobial 56 resistant strains. Genome sequencing can be used to detect infections in samples collected 57 directly from patients, without the need to grow any microorganisms in a laboratory first, 58 and this has already been demonstrated for gonorrhoea using urine samples. With enough 59 sequence information it is also possible to detect antimicrobial resistance (AMR), allowing 60 both detection of infection and information on treatment choices from the same test. This 61 study assesses a method for enriching N. gonorrhoeae sequence data from urine and 62 urethral swabs, and analyses the impact of enrichment on the detection of genes known to 63 cause antibiotic resistance. We show that enriching for *N. gonorrhoeae* DNA prior to 64 sequencing can improve the detection of some AMR genes, and by testing several samples 65 at the same time we can reduce the costs associated with this method. 66

5. Data summary 67

68 The sequence data generated in this study are deposited in the European Nucleotide Archive 69 (ENA, https://www.ebi.ac.uk/ena/browser/) and are publicly available under study code 70 PRJEB64347. The authors confirm all supporting data, code and protocols are provided 71 within the article or through supplementary data files.

72

6. Introduction 73

74 Multi-drug resistant Neisseria gonorrhoeae infection presents a significant global public

- 75 health risk(1), with resistance to ceftriaxone and/or azithromycin detected in countries
- 76 worldwide(2-4). Additionally, cases of N. gonorrhoeae infection are increasing. In 2019,
- 77 117,881 cases were reported in the EU/EEA, over half of which were reported in the UK with

116 cases/100,000 population(5). Early detection and effective treatment is vital to prevent 78 79 the spread of drug-resistant strains.

80

81 Metagenomic sequencing (mNGS) directly from clinical samples offers the potential to

- 82 reduce the time to diagnosis and can provide additional information such as detection of
- 83 antimicrobial resistance(6), particularly useful in settings where culture is not routine. mNGS
- has previously been used to both identify N. gonorrhoeae(7) and detect antimicrobial 84
- 85 resistance (AMR) determinants(8) directly from urine samples. A limitation of mNGS is the
- 86 high levels of contaminating human DNA present in extracts from clinical samples which
- 87 limits the amount of pathogen sequence data generated(6). Target enrichment is a technique that allows enrichment of genomes or genomic regions of interest prior to 88
- 89 sequencing: Biotinylated RNA oligonucleotide probes, designed to target specific sequences,
- 90 allow capture and enrichment of these regions of interest by hybridisation and magnetic
- 91 pulldown. Target enrichment has previously been demonstrated to improve the amount of
- 92 pathogen sequence generated from mNGS(9–11), improving genome coverage and
- 93 detection of AMR determinants(12).
- 94

95 This study assesses the ability of probe-based target enrichment to enrich for N.

96 gonorrhoeae DNA directly from urine and urethral swab samples for the detection of AMR

97 determinants using the Oxford Nanopore Technologies (ONT) sequencing platform. We also

- 98 tested the efficiency of target enrichment after multiplexing samples together, aiming to
- 99 reduce the costs associated with both probe-based enrichment and sequencing.
- 100

7. Methods 101

102 7.1 Samples

Samples were selected from those collected as part of a wider study, conducted with NHS 103 104 Research Ethics approval (reference 19/EM/0029). Participants were recruited at sexual 105 health clinics at Oxford University Hospitals NHS Trust, UK, and University Hospitals Sussex 106 NHS Trust, Brighton, UK. Male patients presenting with symptomatic urethritis were eligible 107 to participate and were recruited following informed consent. In Brighton, urine samples were collected into universal tubes containing boric acid (Medline Scientific) for stabilization 108 109 during transportation to Oxford. In Oxford, samples were collected into universal tubes 110 without boric acid. Urethral swabs were placed into Sigma VCM preservation medium 111 (MWE). All samples were tested for *N. gonorrhoeae* using the BD Viper system (Becton 112 Dickinson), with confirmatory testing for *N. gonorrhoeae* undertaken using the BD Max 113 platform (Oxford) or with the FTD gonorrhea confirmation NAAT assay (Fast Track 114 Diagnostics) (Brighton). Antimicrobial susceptibility testing of cultured bacteria from urethral 115 swabs was performed manually according to EUCAST methods by disc diffusion (for nalidixic 116 acid, penicillin, azithromycin, cefuroxime and ciprofloxacin) and E-tests (for cefixime and 117 cefotaxime) in Brighton, and by E-tests (for ciprofloxacin, azithromycin and ceftriaxone) in 118 Oxford.

120 Custom probe capture library design 7.2

A SureSelectXT custom probe library was designed with Agilent, the manufacturer, to cover 121 122 17 closed genomes of *N. gonorrhoeae* identified by the authors to represent the diversity 123 present across the *N. gonorrhoeae* species (Table S1). Additionally, probes designed to cover 124 genes known to confer antimicrobial resistance in N. gonorrhoeae were represented 10-fold 125 in the final library (Table S2). The final probe library consisted of consisting of approximately

- 126 50,000 120mer RNA probes.
- 127

128 7.3 DNA extraction, library preparation and sequencing

129 DNA was extracted from nucleic acid amplification test (NAAT)-positive urine samples and 130 urethral swabs using the QIAamp UCP pathogen mini kit (Qiagen), as previously

131 described(7). Samples without enrichment were prepared for sequencing on version 9.4.1

132 flow cells following library preparation with the rapid PCR barcoding kit (SQK-RPB004, ONT)

133 also as previously described(7). One sample was run per flow cell on a GridION sequencer.

- 134 For SureSelect enrichment, samples were prepared following the Sequence Capture protocol
- 135 (ONT), using the ligation kit (SQK-LSK110, ONT) for sequencing with a single sample per flow cell.
- 136
- 137

138 7.4 Preparation for multiplexed sequencing

139 To test the feasibility of multiplexing, 4 samples were barcoded with a modified protocol

140 using the rapid PCR barcoding kit (SQK-RPB004, ONT). Briefly, 200ul DNA extract was

141 fragmented by tagmentation in a 10 μ l reaction with 2.5 μ l FRM, then barcoded by PCR in a

double volume reaction for 17 cycles with a 5-minute elongation time at 65°C. Post-PCR, 142

143 barcoded DNA was processed following a modified Sequence Capture protocol, as follows.

144 DNA was end-repaired and PCR adapters ligated as per the original protocol. The initial PCR

145 was omitted, and instead equimolar amounts of each barcoded, amplified sample were

146 pooled together prior to hybridisation with the custom probes. Post-hybridisation, the

Sequence Capture protocol was followed as described by ONT and enriched DNA was 147

148 prepared for sequencing using the ligation kit, as above.

149

150 Illumina sequencing of cultured isolates 7.5

151 Cultures from those samples with a viable stock were prepared for sequencing on an 152 Illumina MiniSeq sequencer. N. gonorrhoeae DNA was extracted from cultured cells grown

153 overnight on chocolate agar at 37°C with 5% CO₂ using the QuickGene DNA tissue kit

(Kurabo) on the QuickGene-Mini80 system (MP Biomedicals), and prepared for sequencing 154

with the Nextera XT DNA library prep kit (Illumina). 155

156

157 **Bioinformatic analysis** 7.6

158 Nanopore sequences were base called and demultiplexed, where necessary, using Guppy

159 (ONT, Version 5.0 or higher) automatically on the GridION sequencer. Sequencing reads

160 classified as human were removed at source with the CRuMPIT workflow, as previously

- described(13). Sequences were mapped to the NC 011035.1 N. gonorrhoeae reference 161
- 162 genome using minimap2 (v2.24-r1122) and variant called with clair2 (v2.1.1). Variants were

- filtered with a random forest classifier, and antimicrobial resistance genes were 163
- 164 characterised from consensus genome sequences or assembled plasmid sequences, both as
- 165 previously described(8). The Nextflow workflow is available at
- https://gitlab.com/ModernisingMedicalMicrobiology/genericbugontworkflow. 166
- 167
- 168 Illumina sequences from cultured isolates were mapped to the NC 011035.1 reference
- 169 genome with SNIPPY(14) v4.6.0 to generate SNP-only consensus sequences. Positions with
- 170 depth lower than 10x coverage were masked as Ns. Hence, both Nanopore and Illumina data
- 171 were mapped to the same reference genome and consensus sequences generated from ONT
- 172 or Illumina-specific variant calling pipelines. Both Illumina and ONT consensus genomes
- 173 were masked for repeat regions using a self-self blast, with a minium window of 200bp and
- 174 90% identity score.
- 175
- 176 A phylogenetic tree was constructed using IQ-TREE v2.1.4-beta(15) and adjusted for
- 177 recombination events using clonalframeML v1.12(16) using the runlistcompare wrapper
- 178 script v0.3.8 (https://github.com/davideyre/runListCompare) for samples with sufficient
- 179 genome coverage.
- 180

181 8. Results

Samples summary 182 8.1

- Twelve urine samples and four urethral swabs were selected for use in this study. Eleven 183
- 184 (11/12, 92%) urines were NAAT-positive for *N. gonorrhoeae* and one (1/12, 8%; sample
- 185 382UB) was NAAT-negative with a corresponding culture-positive urethral swab. All four
- 186 (100%) urethral swabs were culture-positive for N. gonorrhoeae, with corresponding urines
- 187 also NAAT-positive. A sample summary is provided in Figure 1 and Figure S1.
- 188
- 189 A total of 9/11 (82%) NAAT-positive urines had an additional corresponding culture-positive
- 190 urethral swab, with 2/11 (18%) being culture-negative. Antimicrobial susceptibility testing 191 results on cultured isolates were used for comparisons with mNGS-based predictions.
- 192 Results were available for 14 urethral swabs (13 tested in Brighton and 1 in Oxford; 9 with
- NAAT-positive urines that were sequenced, 1 with a NAAT-negative urine that was 193
- 194 sequenced, and 4 where the urethral swab was sequenced). All were sensitive to both
- 195 cephalosporins and azithromycin (Table 1). For guinolone susceptibility, the single sample
- 196 from Oxford (80U) was sensitive to ciprofloxacin, and of the Brighton samples 3/13 (23%)
- 197 were sensitive and 10/13 (77%) resistant to nalidixic acid (Table 1). Brighton additionally
- 198 tested for susceptibility to penicillin (sensitive in 2/13 (15%)) and for the presence of beta-
- 199 lactamase (detected in 9/13, 69%).

200 Effect of enrichment on Neisseria gonorrhoeae genome coverage 8.2

- 201 Probe enrichment increased the proportion of *N. gonorrhoeae* sequencing reads compared
- 202 to no enrichment and did not affect the total sequencing output of the runs (Figure 2). A
- 203 comparison of total bases, bases classified as N. gonorrhoeae plus genome coverage breadth
- and depth before and after enrichment is provided in Table 2. The total number of bases per 204
- 205 sample was similar between enriched (median 10.9Gb, IQR 8.1-17.3) and without
- 206 enrichment (median 9.4Gb, IQR 8.4-10.8). Multiplexing samples onto a single flow cell

207 reduced the number of bases per sample, as expected (median 478Mb, IQR 321-918) (Figure 208 2a). The median proportion of bases classified as *N. gonorrhoeae* increased from less than 0.5% of total sample bases without enrichment (median 0.05%, IQR 0.01-0.1) to more than 209 210 75% with enrichment (median 76%, IQR 42-82). Probe enrichment with multiplexing 211 generated a lower median proportion of *N. gonorrhoeae* bases (33%, IQR 26-45) (Figure 2b). 212 Average coverage depth of aligned reads increased from a median 5-fold (IQR 4.4-6.7) 213 without enrichment to 2405-fold after enrichment (IQR 492-5423) and 63-fold (IQR 36-153) 214 after multiplexed enrichment (Figure 2c). This resulted in all but two samples enriched with 215 SureSelect probes achieving >96.5% of their genome sequenced at a depth of 300-fold or 216 more (Table 2). Comparison of genome coverage with and without enrichment demonstrates 217 no evidence that any bias was introduced by the Sequence Capture protocol (Figure 3).

218

219 Enrichment failed for two samples (265UB, 321UB). Genome coverage breadth and depth

- 220 were similar before and after enrichment: 59% breadth and 3.8-fold depth before and 73%
- 221 breadth and 5-fold depth after for sample 265UB, and 58% breadth and 4.4-fold depth
- 222 before and 53% breadth and 4-fold depth after for sample 321UB. Due to the high cost of
- 223 reagents and the need to order these in batches, we were unable to repeat these
- 224 experiments. A detailed summary of all sequence data generated is provided in Table S3.
- 225

226 8.3 **Detection of antimicrobial resistance determinants**

227 Our previous study determined that a minimum 20-fold genome coverage depth is required 228 for robust AMR prediction(8). In this study 13/15 (87%) of samples achieved this after 229 enrichment, with a minimum coverage depth of 314-fold (Table S4). Sequence data was 230 interrogated for variants within genes known to confer resistance to macrolides, quinolones, 231 cephalosporins, and for the presence of plasmid-mediated genes conferring resistance to 232 penicillin and tetracycline (Table S4). None of the samples in this study were phenotypically 233 resistant to cephalosporins or azithromycin, and no genetic determinants known to confer 234 resistance to these were detected, despite >140-fold coverage of mtrR and >90-fold 235 coverage of *penA*, *ponA* and *porB* in those samples with successful enrichment (Figure 4). Ten 236 (10/16, 63%) samples were reported as resistant to nalidixic acid. Mutations in gyrA (S91F, 237 D95G) were detected in two samples before enrichment. After enrichment, gyrA was 238 sequenced to a depth of at least 115-fold and mutations were detected in 9/9 (100%) of 239 those samples with singleplex enrichment: singleplex enrichment sequence data was not 240 available for one sample (347UB). Additionally, gyrA mutations S91F and D95G were found 241 in sample 361UB after enrichment, which did not grow in culture and therefore had no 242 susceptibility data reported by the microbiology laboratory.

243

244 For plasmid-mediated resistance, no sequence data containing ermB, ermC, ermF or mef was 245 detected, corresponding with laboratory results of susceptibility to azithromycin. Beta-246 lactamase was detected in 9/16 (56%) samples by the laboratory, and sequencing without 247 enrichment detected the presence of *blaTEM-1* in 6 of these samples, and additionally in 248 sample 361UB which did not have susceptibility data reported After enrichment, *blaTEM-1* 249 was only detected in 2 samples using the criteria defined previously(8), and in 3 samples 250 when considering coverage breadths lower that the predefined cutoff threshold. Both 251 samples detected above the threshold were positive by laboratory testing, and one of which 252 was an additional detection over no enrichment. Although the samples were not tested for

253 susceptibility to tetracycline, tetM was detected in 3 samples before enrichment and five 254 samples after enrichment (4 above and one below the cutoff threshold).

255

256 Despite 10-fold representation in final probe library, the AMR genes assessed in this study 257 did not demonstrate a higher coverage depth than the rest of the genome (Figure S2). We

- 258 also observed uneven enrichment across the target AMR genes, with poor improvements in
- 259 coverage of the 23S gene after enrichment (median (IQR) coverage depth before enrichment
- 260 of 1.6 (1.0-3.4) and after enrichment of 6.7 (3.6-12.5)).
- 261

262 8.4 **Evaluation of multiplexing prior to enrichment**

263 Four samples (80U, 303D, 347UB, 367UB) were multiplexed before hybridisation with the 264 SureSelect probes. The multiplexed run generated 8.2 gigabases (Gb) of sequence data. 265 Once bases from misclassified barcodes and unclassified bases were removed, 1.7Gb were classified as bacterial and, despite enrichment, 1.4Gb classified as human. The median 266 267 number of bacterial bases classified as N. gonorrhoeae was 111 megabases (Mb) (IQR 55-268 305), with a median *N. gonorrhoeae* single-fold genome coverage of 77% (IQR 67-85) (Table 269 3). In comparison to no enrichment, multiplexed enrichment achieved a median 12-fold (IQR 270 4.8-33) improvement in genome coverage depth, which is less than the median 365-fold 271 (IQR 112-720) improvement seen after singleplex enrichment (Table 2). Despite hybridisation 272 of equimolar amounts of barcoded DNA with the SureSelect probes there was uneven 273 coverage across the 4 samples, with >700Mb separating the highest and lowest number of 274 bases classified as N. gonorrhoeae.

275

276 All 4 samples achieved genome coverage depth of greater than 20-fold (Table 3), which is the 277 minimum depth required for robust detection of AMR determinants(8). Three of the four 278 were resistant to a quinolone (nalidixic acid; 303D, 347UB, 367UB) and one was sensitive 279 (ciprofloxacin, 80U). Depth was insufficient to resolve the sequence of the gyrA or parC 280 genes in any sample without enrichment, and after multiplexed enrichment adequate depth 281 was achieved to detect mutations in gyrA (S91F) in 2/3 resistant samples (303D and 367UB). 282 Sequencing depth was inadequate to determine resistance in sample 347U, with only 7-fold 283 coverage depth of gyrA. blaTEM-1 was detected in samples 303D and 367UB without 284 enrichment, corresponding with the presence of beta-lactamase detected by the laboratory, 285 but was not detected in sample 347UB despite detection by the lab. After multiplexed 286 enrichment, *blaTEM-1* was detected below the cutoff threshold in 1/3 samples reported 287 positive by the laboratory, and in an additional sample without laboratory results (80U).

288

289 8.5 Assesssment of relatedness and comparison of Nanopore with Illumina sequence 290 data

291 Comparison of Nanopore (from urine and swab sequencing) and Illumina genomes (from 292 isolate sequencing) in a phylogenetic tree showed concordance between the sequencing 293 methods, demonstrating the ability to infer relatedness: 13/15 (87%) samples had 294 singleplexed enrichment Nanopore data and 11/15 had Illumina data for analysis, giving a 295 total of 11 samples with paired Nanopore and Illumina data (Figure 5). The median (IQR) 296 [range] number of SNPs detected between Nanopore and Illumina sequence pairs generated 297 from matched urine/swab samples and cultured isolates from the same patient was 44 (38-

- 298 52) [24-245]. This likely represents a combination of sequencing artefact and true 299 differences between the samples.
- 300
- 301 Samples genetically further away from the reference genome used showed greater
- 302 differences between Illumina and Nanopore results, with samples 303D, 342UB and 358UB
- 303 forming sequencing technology-specific clades instead of grouping by patient, as seen in all 304 the other samples.
- 305
- 306 Two samples without enrichment (202D, 301D) generated enough genome coverage for 307 inclusion in this analysis and were almost identical to their corresponding SureSelect-308 enriched pair (2 and 0 SNPs different, respectively). Only one multiplexed sample, 303D,
- 309 generated enough data to reconstruct the genome for this analysis.
- 310

9. Discussion 311

- 312 This study demonstrates the utility of target enrichment for the culture-free detection of
- 313 Neisseria gonorrhoeae directly from urine and urethral swabs by sequencing. We also show,
- 314 for the first time with Nanopore sequencing, that target enrichment can be achieved after
- 315 multiplexing of samples prior to enrichment.
- 316

317 Where enrichment was successful it was possible to achieve >96.5% genome coverage 318 breadth at a depth of 300-fold or greater, representing a minimum 40-fold improvement in

- 319 coverage depth. Multiplexing with enrichment still provided >20-fold coverage depth in all
- 320 samples tested. The depth and breadth of N. gonorrhoeae genome coverage achieved after
- 321 enrichment enabled detection of gyrA mutations known to confer resistance to quinolones
- 322 in all samples with enriched sequence data reported as resistant to nalidixic acid, and
- additionally detected mutations in a sample with no susceptibility data due to failed growth 323
- 324 on culture. Targeted enrichment allowed sequencing at high depth of other chromosomal
- 325 genes known to confer antimicrobial resistance, e.g., the mtrR gene where a mutation at
- 326 amino acid position 45 confers both multi-drug and macrolide resistance. This offers
- 327 confidence that resistance should be detected if it were present.
- 328
- 329 mNGS holds promise for use in routine clinical diagnostics(17) but is hampered by high levels 330 of host DNA, which dominates when nucleic acid is extracted directly from a sample without 331 initial culture, and subsequently overwhelms the sequence data such that information on 332 pathogens is often very limited (for example(18)). Target enrichment enables selection of the 333 genome of interest over contaminating host DNA, and is useful where the target pathogen is 334 known in advance of the diagnostic test. Prevalence of multi-drug resistant N. gonorrhoeae 335 and the need for a fast diagnostic that can detect both the pathogen and any corresponding 336 antimicrobial resistance makes targeted sequencing an appealing prospect.
- 337
- 338 Susceptibility testing relies on culture, but N. gonorrhoeae can sometimes be difficult to 339 grow in the laboratory. This study demonstrates the additional value of sequencing with
- 340 enrichment, detecting gyrA mutations with a mean coverage depth of 116-fold in a sample 341 that did not grow in culture.
- 342

Detection of plasmid-mediated resistance genes was less successful, with enrichment 343

344 missing detection of beta-lactamase known to be present by laboratory testing in the

345 majority of samples, and despite detection of *blaTEM-1* in the sequence data of six samples

346 before enrichment. Inefficient amplification of plasmid DNA pre-hybridisation, or the short

347 SureSelect probes not effectively pulling out the plasmid-bound gene during hybridisation,

348 could be possible explanations for the unsuccessful detection of *blaTEM-1* but further work

- 349 is required to determine the exact reason.
- 350

351 Two samples failed enrichment. Analysis of their post-enrichment sequence data identified

- 352 predominantly laboratory kit-based contaminants in addition to low numbers of reads
- 353 mapping to *N. gonorrhoeae*. We propose that this is due to the very low amount of *N*. 354 *gonorrhoeae* DNA in the original urine extract for these two samples, as has been described
- 355 by others studying low bacterial load samples(19,20).
- 356

357 Multiplexing allowed a median 12-fold improvement in genome coverage when four 358 samples were barcoded and pooled prior to hybridisation and detection of relevant AMR 359 determinants. Demultiplexing samples after sequencing leads to loss of data as some reads 360 remain unclassified due to a barcoding score lower than the default requirement in Guppy. 361 The larger than expected number of unclassified reads generated from the multiplexed 362 samples could be a consequence of the combination of barcoding and ligation library preparation used to prepare these samples, but further work would be required to 363 364 determine this. The number of unclassified reads could potentially be reduced by changing 365 the minimum barcoding score requirements, although this carries the risk of increased false-366 positive calls.

367

368 Other limitations of this study include the large starting amount of DNA required for this 369 hybridisation method. Often, DNA extracts directly from clinical samples fail to generate the 370 required 3.5µg required for the ONT Sequence Capture protocol. Extracts from urine and 371 urethral swabs do, in general, achieve the required amount of DNA. However, samples from 372 sterile sites without much host DNA contamination, for example CSF samples, or from 373 samples with a limited volume or size, would not be good candidates for probe-based 374 enrichment with Nanopore sequencing. The method is performed over two days, with a 16-375 hour overnight hybridisation, which makes it a lengthy assay. Although there could 376 potentially be some optimisation of the protocol, it currently cannot compete with the time 377 it takes to perform a NAAT or other molecular assay, but is still likely faster than culture. 378 There are also limitations arising from artefacts introduced by ONT sequencing, as seen for 379 some samples in Figure 5. However, this study was performed with version 9.4.1 flowcells, 380 and the more recent generation of flowcells, versions 10 onwards, may address this(21). In 381 our data we observed uneven enrichment across target AMR genes, with the 23S gene in 382 particular under-represented in enriched sequence data. Future work could optimise probes 383 in this region of the genome to increase coverage of this important gene. 384

385 The nucleic acid amplification tests are a reliable method for detecting *N. gonorrhoeae* but 386 cannot give the whole picture of AMR, an important consideration given the increasing prevalence of multi-drug resistant gonorrhoea. This study demonstrates sequencing with 387 388 target enrichment can enable high-depth chromosomal antimicrobial resistance gene

- 389 characterisation and relatedness detection that was not previously possible for these sample
- 390 types with direct metagenomic sequencing. Additionally, multiplexing prior to enrichment
- 391 allows higher sample throughput and reduction in the costs associated with both probe-
- 392 based enrichment and sequencing.

393 **10. Figures**



394395 Figure 1. Sample summary. Figure created with BioRender





396 397

Figure 2. Comparison of sequence data before and after enrichment. Total number of bases per 398 sequencing run (A); Percentage of bases classified as N. gonorrhoeae (B); Average coverage depth 399 of N. gonorrhoeae genome per sequencing run (C) for samples sequenced without enrichment 400 (orange), with singleplex enrichment (blue) or with enrichment in a multiplex of 4 samples (black).

401



404 Figure 3. Genome coverage depth for samples sequenced without enrichment (orange), with singleplex enrichment (blue) or with enrichment in a

405 multiplex of 4 samples (black). Sample 347 has sequence data without enrichment and with multiplexed enrichment only. Short regions of low coverage

406 seen in blue represent areas of divergence between the sample and the reference genome used for mapping and/or the genomes included in the probe

407 set. The similar troughs seen with the orange and blue lines suggest that divergence from the reference genome is the most likely explanation, rather

408 than a gap in the probe set.





409 410

- Figure 4. Comparison of mean coverage depth for 7 antimicrobial resistance determinants before
- 411 and after target enrichment. Different colours are used for each sample pair with and without 412 enrichment.



413

414 Figure 5. Maximum likelihood tree of genomes generated from consensuses sequences, comparing

415 the same samples sequenced with Illumina (red), Nanopore with no enrichment (green), Nanopore

416 with singleplex enrichment (blue) and Nanopore with multiplexed enrichment (purple). Sample

417 364 has three Illumina sequences generated from two rectal swab cultures (not included in

418 enrichment and singleplex sequencing) and one urethral swab culture.

11. Tables 419

Sample	Sample type for culture	Sample type for sequencing	Ciprofloxacin/ Nalidixic acid	Cephalosporins	Azithromycin	Penicillin	B-lactamase*
80U	Urethral swab	Urine	S	S	S	no test	no test
202D	Urethral swab	Urethral swab	S	S	S	S	Ν
265UB	Urethral swab	Urine	R	S	S	S R	
301D	Urethral swab	Urethral swab	R	S	S I		Ν
303D	Urethral swab	Urethral swab	R	S	S	R	Р
304D	Urethral swab	Urethral swab	S	S	S	I	N
305UB	Urethral swab	Urine	R	S	S	R	Р
318UB	No growth on culture	Urine					
321UB	Urethral swab	Urine	S	S	S	S	N
342UB	Urethral swab	Urine	R	S	S	R	Р
347UB	Urethral swab	Urine	R	S	S	R	Р
358UB	Urethral swab	ethral swab Urine R S S		S	R	Р	
361UB	No growth on culture	Urine					
364UB	Urethral swab	Urine	R	S	S S R		Р
367UB	Urethral swab	Urine	R	S	S R		Р
382UB	Urethral swab	Urine	R	S	S	R	Р

420

421 Table 1. Antimicrobial susceptibility results. S, sensitive; I, intermediate; R, resistant; *for B-lactamase,

422 N denotes susceptible; P denotes possible resistance.

	Without enric	chment			With singleplex				
Sample name	Ngon bases	Total bases	Genome coverage breadth (%)	Average coverage depth	Ngon bases	Total bases	Genome coverage breadth (%)	Average coverage depth	Coverage depth fold- enrichment, singleplex vs no enrichment
80U	749179	8434029003	3.46	7.98	1280208433	3782522608	97.44	314.12	39.3
202D	4184726	9656053514	35.73	4.45	1550689332	13895666698	98.53	536.27	120.6
265UB	5949401	11386449183	58.55	3.82	17922316	8014502433	73.45	5.01	1.31
301D	35361341	7933536503	98.83	14.36	14947146476	17150934403	99.80	5413.55	377.0
303D	9692745	9439958602	82.96	4.73	17664552591	21087141427	97.08	6637.14	1403.8
304D	1937846	7906566477	17.88	4.32	1790026178	3038176523	97.49	447.24	103.5
305UB	12659589	9391830588	86.68	5.53	14039629756	17449531128	96.75	5432.74	983.0
318UB	62722932	8544860509	96.36	25.72	16557094125	20163378663	97.03	6295.03	244.8
321UB	7745538	12127667362	57.53	4.38	9600291	6880830294	53.10	4.02	0.92
342UB	4929172	14056225894	51.44	3.75	6489125469	10636014129	96.70	1724.94	460.4
358UB	1399857	11292620134	10.46	5.22	15428552493	20118811661	97.09	5905.35	1131.6
361UB	698401	8371283598	3.78	7.05	7748292558	10234243279	99.04	2576.51	365.4
364UB	4923268	8765729938	51.80	3.64	8974767733	10869934865	96.84	3304.73	908.2
367UB	1474533	10579314587	12.82	4.52	6713863610	8261193715	96.63	2405.44	532.2
382UB	12826754	1949351698	71.43	6.52	5518490118	11085690959	96.73	1552.06	238.2

423

424 Table 2. Summary of bases classified as *N. gonorrhoeae* (Ngon), total bases, single-fold genome coverage breadth, and average genome coverage depth

425 for all samples before and after singleplex enrichment.

	Without enrichment			With singleplex enrichment			With multiplex enrichment			
Sample	Total Ngon bases	Genome coverage breadth (%)	Average coverage depth	Total Ngon bases	Genome coverage breadth (%)	Average coverage depth	Total Ngon bases	Genome coverage breadth (%)	Average coverage depth	Coverage depth fold-enrichment, multiplex vs no enrichment
80U	749179	3.46	7.98	1280208433	97.44	314.12	96384278	71.91	40.05	5.02
303D	9692745	82.96	4.73	17664552591	97.08	6637.14	1144125623	94.61	352.47	74.5
347UB	1066606	7.23	5.69	No singleplex data available			47875172	52.70	48688685	4.07
367UB	1474533	12.82	4.52	6713863610	96.63	2405.44	238397019	82.44	85.96	19.0

427

428 Table 3. Comparison of no enrichment, singleplex enrichment and multiplex enrichment. Total bases classified as *N. gonorrhoeae* (Ngon), single-fold genome

429 coverage breadth, and genome coverage depth reported for the 4 samples sequenced as a multiplex.

430 12. Author statements

431 **12.1** Author contributions

432 TLS, NDS, ML and DWE designed the study. NDS conducted the bioinformatics analysis. TLS,

- 433 LB and JK performed laboratory experiments. KC organised clinical samples, performed
- 434 culturing and collated metadata for samples collected in Brighton. TLS, NDS and DWE
- 435 prepared the manuscript. The GonFast Investigators Group recruited patients and collected
- 436 samples. All authors read and contributed to the manuscript.
- 437

438 12.2 Conflicts of interest

- 439 The authors declare no conflicts of interest.
- 440

441 **12.3** Funding information

- 442 This study was funded by the Centers for Disease Control and Prevention, USA.
- 443 This study was also supported by the National Institute for Health Research (NIHR) Oxford
- Biomedical Research Centre (BRC). The funders had no role in study design, data collection
- and interpretation, or the decision to submit the work for publication. The views expressed
- 446 are those of the authors and not necessarily those of the NHS, NIHR or Department of
- 447 Health. DWE is a Robertson Foundation Big Data Institute Fellow.
- 448

449 12.4 Ethical approval

- 450 This study was conducted with NHS Research Ethics committee approval (reference
- 451 19/EM/0029).
- 452

453 12.5 Acknowledgements

- 454 We thank the microbiology laboratory staff of Oxford University Hospitals NHS Foundation
- Trust and the University Hospitals Sussex NHS Foundation Trust for providing assistance with sample collection.
- 457 The GonFast Investigators Group includes Joanna Rees and Emily Lord (Oxfordshire Sexual
- 458 Health Service, Oxford University Hospitals NHS Foundation Trust, Oxford); and Suneeta
- 459 Soni, Celia Richardson, Joanne Jessop, and Tanya Adams (Brighton and Hove sexual health
- 460 and contraception service, Royal Sussex County Hospital, Brighton).
- 461

462 **13. References**

- Unemo M, Shafer WM. Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st
 Century: Past, Evolution, and Future. Clin Microbiol Rev. 2014 Jul;27(3):587–613.
- 465 2. Eyre DW, Town K, Street T, Barker L, Sanderson N, Cole MJ, et al. Detection in the
 466 United Kingdom of the Neisseria gonorrhoeae {FC428} clone, with ceftriaxone resistance
 467 and intermediate resistance to azithromycin, October to December 2018. Euro Surveill.
 468 2019 Mar;24(10).

medRxiv preprint doi: https://doi.org/10.1101/2024.01.09.24301039; this version posted January 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Golparian D, Vestberg N, Södersten W, Jacobsson S, Ohnishi M, Fang H, et al. 469 3. 470 Multidrug-resistant Neisseria gonorrhoeae isolate SE690: mosaic penA-60.001 gene 471 causing ceftriaxone resistance internationally has spread to the more antimicrobial-472 susceptible genomic lineage, Sweden, September 2022. Eurosurveillance [Internet]. 2023 473 Mar 9 [cited 2023 Apr 27];28(10). Available from: 474 https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.10.2300125 475 4. Sawatzky P, Demczuk W, Lefebvre B, Allen V, Diggle M, Hoang L, et al. Increasing 476 Azithromycin Resistance in Neisseria gonorrhoeae Due to NG-MAST 12302 Clonal Spread 477 in Canada, 2015 to 2018. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e01688-21. 478 5. European Centre for Disease Prevention and Control. Gonorrhoea. In: ECDC. Annual 479 Epidemiological Report for 2019. Stockholm: ECDC; 2023 [Internet]. [cited 2023 Apr 27]. Available from: https://www.ecdc.europa.eu/en/publications-data/gonorrhoea-annual-480 epidemiological-report-2019 481 482 6. Chiu CY, Miller SA. Clinical metagenomics. Nat Rev Genet. 2019 Jun;20(6):341–55. 483 7. Street TL, Barker L, Sanderson ND, Kavanagh J, Hoosdally S, Cole K, et al. Optimizing 484 DNA Extraction Methods for Nanopore Sequencing of Neisseria gonorrhoeae Directly 485 from Urine Samples. J Clin Microbiol [Internet]. 2020 Feb 24 [cited 2020 Jul 3];58(3). 486 Available from: https://jcm.asm.org/content/58/3/e01822-19 487 8. Sanderson ND, Swann J, Barker L, Kavanagh J, Hoosdally S, Crook D, et al. High precision Neisseria gonorrhoeae variant and antimicrobial resistance calling from 488 metagenomic Nanopore sequencing. Genome Res [Internet]. 2020 Sep 1 [cited 2020 Sep 489 490 14]; Available from: http://genome.cshlp.org/content/early/2020/09/01/gr.262865.120 491 9. Cai W, Nunziata S, Rascoe J, Stulberg MJ. SureSelect targeted enrichment, a new cost 492 effective method for the whole genome sequencing of Candidatus Liberibacter asiaticus. 493 Sci Rep. 2019 Dec 12;9(1):18962. 494 Brown AC, Bryant JM, Einer-Jensen K, Holdstock J, Houniet DT, Chan JZM, et al. Rapid 10. 495 Whole-Genome Sequencing of Mycobacterium tuberculosis Isolates Directly from Clinical 496 Samples. Land GA, editor. J Clin Microbiol. 2015 Jul;53(7):2230-7. 497 11. Bowden KE, Joseph SJ, Cartee JC, Ziklo N, Danavall D, Raphael BH, et al. Whole-498 Genome Enrichment and Sequencing of Chlamydia trachomatis Directly from Patient 499 Clinical Vaginal and Rectal Swabs. Rasmussen AL, editor. mSphere. 2021 Apr 500 28;6(2):e01302-20. 501 Doyle RM, Burgess C, Williams R, Gorton R, Booth H, Brown J, et al. Direct Whole-

12. 502 Genome Sequencing of Sputum Accurately Identifies Drug-Resistant Mycobacterium 503 tuberculosis Faster than MGIT Culture Sequencing. Mellmann A, editor. J Clin Microbiol. 504 2018 Aug;56(8):e00666-18.

- 505 13. Sanderson ND, Street TL, Foster D, Swann J, Atkins BL, Brent AJ, et al. Real-time
 506 analysis of nanopore-based metagenomic sequencing from infected orthopaedic devices.
 507 BMC Genomics. 2018 Sep;19(1):714.
- 508 14. Seemann, Torsten. Snippy: Rapid haploid variant calling and core genome alignment
 509 [Internet]. 2015. Available from: https://github.com/tseemann/snippy
- 510 15. Nguyen LT, Schmidt HA, Von Haeseler A, Minh BQ. IQ-TREE: A Fast and Effective
 511 Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies. Mol Biol Evol. 2015
 512 Jan;32(1):268–74.
- 51316.Didelot X, Wilson DJ. ClonalFrameML: Efficient Inference of Recombination in Whole514Bacterial Genomes. Prlic A, editor. PLOS Comput Biol. 2015 Feb 12;11(2):e1004041.
- 51517.Miller S, Chiu C. The Role of Metagenomics and Next-Generation Sequencing in516Infectious Disease Diagnosis. Clin Chem. 2021 Dec 30;68(1):115–24.
- 517 18. Street TL, Sanderson ND, Atkins BL, Brent AJ, Cole K, Foster D, et al. Molecular
 518 Diagnosis of OrthopedicDevice-Related Infection Directly from Sonication Fluid by
 519 Metagenomic Sequencing. J Clin Microbiol. 2017;(August):JCM.00462-17.
- 520 19. Salter SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, Moffatt MF, et al. Reagent and
 521 laboratory contamination can critically impact sequence-based microbiome analyses.
 522 BMC Biol. 2014 Nov 12;12(1):87.
- Paniagua Voirol LR, Valsamakis G, Yu M, Johnston PR, Hilker M. How the 'kitome'
 influences the characterization of bacterial communities in lepidopteran samples with low
 bacterial biomass. J Appl Microbiol. 2021 Jun 1;130(6):1780–93.
- 526 21. Ni Y, Liu X, Simeneh ZM, Yang M, Li R. Benchmarking of Nanopore R10.4 and R9.4.1
 527 flow cells in single-cell whole-genome amplification and whole-genome shotgun
 528 sequencing. Comput Struct Biotechnol J. 2023;21:2352–64.